Go to the list of all blogs
Anna G's Avatar
published in Blogs
Aug 17, 2022
TickeronGET DAILY SIGNALS
Absa (AGRPY,$22.99) earnings rose +27% in H1, on revenue growth

Absa (AGRPY,$22.99) earnings rose +27% in H1, on revenue growth

Absa Group headline earnings rose +27% to Rands 11 billion in the first half of the year, bolstered by revenue growth.

The African financial services company’s revenue for the first half climbed +14%, on the back of growth across business segments, a rebound in the insurance business in South Africa, and rising interest rates across key markets.

Absa’s net interest income rose +12%, and  non-interest income grew +18%.

“All of our key measures are significantly above the pre-Covid levels of the first half of 2019,” said Jason Quinn, Absa Group Financial Director. “The strategic decisions we made in the last few years have ensured that we remain capital generative and we are appropriately provisioned as we face a tougher environment,” he mentioned.

Related Ticker: AGRPY
View a ticker or compare two or three
Ask AI
VS
Compare
VS
Compare
Interact to see
Advertisement
A.I.Advisor
published price charts
View AI-Driven Trading for AGRPY
A.I. Advisor
published General Information

General Information

Industry RegionalBanks

Industry
N/A
Address
15 Troye Street
Phone
+27 113504000
Employees
35451
Web
https://www.absa.africa
Related Blogs
LOB

Coastal Financial (CCB) and Live Oak Bancshares (LOB): Weighing Two Distinct Banking Approaches

BBD

BBD vs ITUB: Brazil's Leading Banks Respond to Shifting Political Winds

SOFI

NU vs SOFI: Nu Holdings and SoFi Technologies Compared

SHFS

Why Is Safe Harbor Financial (SHFS) Stock Up 1065% Today?

DB

DB vs LYG: Deutsche Bank and Lloyds Banking Group Compared

View all blogs related to
#RegionalBanks
Interesting Articles

How Do I Invest Money in My Cash-Balance Plan?

AA+/Aa1 — credit rating

What is the Investment Company Act of 1940?

What is IRS Publication 529 on Miscellaneous Deductions?

Will Ripple Make a Superior Payment System?

View all articles
Interact to see
Advertisement

U-BX Technology Ltd. (UBXG): +79% Surge in 30 Days Signals Insurtech Momentum

UBXG stock surged +79% over the last 30 days, driven by heightened trading volume and positive market sentiment amid broader technology sector trends. Over the past quarter, the stock rose +61%, reflecting recovery from earlier lows near its 52-week bottom.
UBXG#AdvertisingMarketingServices
Joma Foster, expert
Apr 02, 2026

Why Commercial Vehicle Group (CVGI) Stock Surged +89% in the Last 30 Days

CVGI stock surged approximately +89% over the last 30 days, driven by strong Q4 2025 earnings beat on revenue and positive 2026 guidance. Over the past quarter, shares rose about +126%, reflecting improved profitability, debt reduction, and a key partnership announcement.
CVGI#AutoPartsOEM
Joma Foster, expert
Apr 02, 2026

XCF Global (SAFX): +104% Surge in 30 Days Amid Capital Raise and Merger Momentum

SAFX stock surged +104% over the past 30 days, driven by positive updates on a $10 million capital raise and merger progress. Over the past quarter, the stock rose +44%, reflecting recovery from lows amid renewable energy sector interest and strategic developments.
SAFT#PropertyCasualtyInsurance
Joma Foster, expert
Apr 02, 2026

LeonaBio (LONA): +80% Surge in 30 Days on Pipeline Momentum and Analyst Upgrades

LONA stock surged +80% over the past 30 days, driven by positive analyst upgrades, executive appointments, and full-year financial updates highlighting pipeline progress. Over the past quarter, shares rose +48%, reflecting improved investor sentiment in biotech amid clinical advancements.
LONA#Biotechnology
Joma Foster, expert
Apr 02, 2026

Lifetime Brands (LCUT): +77% Surge in 30 Days on Earnings Strength and Strong Buy Rating

Lifetime Brands (LCUT) stock surged +77% over the last 30 days, driven by a strong Q4 earnings beat and a Zacks Rank #1 (Strong Buy) upgrade that reflects an improved earnings outlook. Over the past quarter, shares rose +48%, supported by profitability gains despite softer sales, with adjusted EBITDA reaching $50.8 million for full-year 2025.
LCUT#HomeFurnishings
Joma Foster, expert
Apr 01, 2026

Torrid Holdings (CURV): +73% Surge in 30 Days Amid Earnings Beat and Store Optimizations

CURV stock surged approximately +73% over the last 30 days, driven primarily by a positive reaction to Q4 and fiscal 2025 earnings that beat expectations on EPS and revenue. Over the past quarter, the stock is up around +55%, reflecting recovery from lows near $1 amid ongoing store optimization and sub-brand launches
CURV#ApparelFootwearRetail
Joma Foster, expert
Apr 02, 2026

Blaize Holdings (BZAI): +72% Surge in 30 Days Amid Earnings Strength and AI Edge Momentum

Blaize Holdings, Inc. (BZAI) focuses on artificial intelligence (AI)-enabled edge computing solutions, offering programmable AI processors and platforms for verticals such as smart cities, defense, retail, and enterprise markets. The company's core revolves around hardware like the Graph Streaming Processor (GSP) AI accelerator, compute cards, and software tools including Blaize AI Studio—a no-code/low-code environment for deploying AI models without source code expertise. Based in El Dorado Hills, California, and founded in 2010, it went public through a merger in early 2025.
BZAI#PackagedSoftware
Joma Foster, expert
Apr 02, 2026

Comstock Holding Companies (CHCI): +65% Surge in 30 Days on Strong Earnings and Expansion

Comstock Holding Companies, Inc. (CHCI) operates as an asset manager, developer, and operator of mixed-use and transit-oriented properties, mainly in the greater Washington, D.C. metropolitan area. The company targets high-growth urban and suburban markets, overseeing a portfolio that spans residential, commercial, hospitality, and parking assets near key metro stations. Its asset-light, fee-based model delivers recurring revenue through property management, leasing, development services, and asset recapitalization for institutional investors, family offices, and governments.
CHCI#RealEstateDevelopment
Joma Foster, expert
Apr 02, 2026

Arm Holdings (ARM): +26% Surge in 30 Days on AI Chip Momentum and Analyst Upgrades

ARM stock surged +26% over the past 30 days, driven by announcements of in-house chip production and strong analyst upgrades amid AI enthusiasm. Over the past quarter, the stock climbed +38%, reflecting robust Q3 earnings beat with 26% revenue growth and data center royalty doubling.
ARM#Semiconductors
Alicia, beginner
Apr 02, 2026

Sable Offshore Corp. (SOC): +92% Surge in 30 Days on Pipeline Restart and Analyst Upgrades

Sable Offshore Corp. (SOC) is an independent oil and gas company focused on offshore operations in federal waters off California. The company owns and operates three platforms in the Santa Ynez Unit (SYU), spanning 16 federal leases across approximately 76,000 acres, along with subsea pipelines for crude oil, natural gas, and produced water transport to onshore facilities. Its core business model centers on restarting and developing prolific fields like the SYU, which had been idle due to regulatory and legal hurdles following a 2015 pipeline spill.
SOC#ContractDrilling
Alicia, beginner
Apr 03, 2026

76% Win Rate, +76.22% Return: How AI Trades Oil & Energy Stocks During Geopolitical Crisis

When geopolitical turmoil sends markets into chaos, most retail traders freeze — but Tickeron's Energy (OXY, EOG, DVN, FANG, APA, MTDR) AI Trading Agent is built to thrive in exactly these conditions. This 15-minute and 60-minute AI-powered robot has delivered a +76.22% annualized return with a 64.21% win rate and a Profit Factor of 2.70 — trading six of the most volatile and opportunity-rich energy tickers on the market.
OXYEOGFANG#OilGasProduction
Apr 01, 2026

+49% Annualized Return: How to Trade Oil & Gas Stocks During War, Sanctions & Energy Shocks with Tickeron's AI Robot

The global energy sector is on fire — literally and figuratively. With crude oil prices swinging 20–30% in response to geopolitical flashpoints, OPEC+ production cuts, and escalating conflicts in Eastern Europe and the Middle East, traders who aren't using AI-powered tools are flying blind. Enter Tickeron's Energy (Oil & Gas – E&P) AI Trading Agent — a 60-minute signal robot built exclusively around five high-impact Exploration & Production tickers, now posting a staggering +49% Annualized Return and +1,251% 30-Day Annualized Return, with $14,703 in closed-trade P&L on a $30,000 simulated balance.
DVNOVVSM#OilGasProduction
Apr 01, 2026

Cheniere Energy Partners (CQP): Navigating LNG Expansion Amid Valuation Caution

From what I see, Cheniere Energy Partners (CQP) holds a commanding position through its ownership and operation of the Sabine Pass LNG terminal in Louisiana, the largest LNG production facility in the U.S. with approximately 30 million tonnes per annum (mtpa) capacity across six trains, alongside the connected Creole Trail Pipeline. This setup makes CQP a leader in U.S. LNG exports, which have accounted for about 11% of global supply in recent years. The company's ~80% contracted production through long-term sale and purchase agreements (SPAs) provides revenue stability, with weighted average remaining lives of around 13 years.
CQP#OilGasPipelines
Apr 01, 2026

Regeneron Pharmaceuticals (REGN): Pipeline Catalysts and Growth Drivers in a Competitive Biotech Landscape

In my view, Regeneron Pharmaceuticals holds a strong leadership position in biotechnology, thanks to its proprietary VelociSuite technologies, including VelocImmune for fully human antibody discovery. This enables a robust pipeline across immunology, oncology, ophthalmology, and rare diseases. The company's integrated model—from discovery to commercialization—drives high R&D productivity, with approximately 45 clinical programs and key partnerships like Sanofi for Dupixent and Bayer for EYLEA.
REGN#Biotechnology
Apr 01, 2026

argenx SE (ARGX): Strong Buy Consensus Signals +30% Upside Amid 2026 Catalysts

As I review argenx SE's place in the market, its strong footing in immunology stands out. This commercial-stage biopharmaceutical company focuses on differentiated antibody therapies for severe autoimmune diseases. The flagship product, VYVGART (efgartigimod), a first-in-class neonatal Fc receptor (FcRn) inhibitor, has secured leadership in generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), with approvals across the U.S., Europe, and Japan. The Immunology Innovation Program (IIP) fuels a robust pipeline, featuring next-generation FcRn candidates like ARGX-213 and ARGX-124, alongside first-in-class assets such as empasiprubart (C2 inhibitor, ARGX-117) and adimanebart (MuSK agonist).
ARGX#Biotechnology
Apr 01, 2026

Alnylam Pharmaceuticals (ALNY): Strong TTR Growth and Pipeline Catalysts Ahead

I've long admired Alnylam Pharmaceuticals as the pioneer in RNA interference (RNAi) therapeutics, a gene-silencing technology that has delivered six approved products, including AMVUTTRA (vutrisiran), ONPATTRO (patisiran), GIVLAARI (givosiran), and OXLUMO (lumasiran). The company's proprietary platform, enhanced by GalNAc conjugation for liver targeting and emerging extra-hepatic delivery innovations, creates a solid competitive moat in precision genetic medicines.
ALNY#Biotechnology
Apr 01, 2026

BeOne Medicines (BONE): Strong Buy Consensus and +117% Revenue Growth Projected for 2026

As I review BeOne Medicines AG's position in the oncology space, what stands out is its role as a global leader with a diversified portfolio that includes both commercial-stage therapies and a deep pipeline targeting hematologic and solid tumors. The flagship product, BRUKINSA (zanubrutinib), a Bruton's Tyrosine Kinase (BTK) inhibitor, has secured approvals in over 75 markets, solidifying its dominance in chronic lymphocytic leukemia (CLL) and other blood cancers. This is complemented by TEVIMBRA (tislelizumab), an anti-PD-1 antibody approved in more than 50 markets for various indications, which broadens its reach in immunotherapy.
ONC#Biotechnology
Apr 01, 2026

Rio Tinto (RIO): Navigating Growth in Copper and Lithium Amid Iron Ore Pressures

Rio Tinto holds a premier position as one of the world's largest mining companies, anchored by low-cost, Tier 1 assets. Its Pilbara iron ore operations in Australia deliver industry-leading margins, thanks to integrated rail and port infrastructure that gives it a structural cost advantage over higher-cost producers. In copper, the company has significant stakes in Escondida, the world's largest copper mine, and full ownership of Oyu Tolgoi in Mongolia, setting it up well to benefit from tightening supply as demand surges for electrification and renewables.
RIO#OtherMetalsMinerals
Apr 01, 2026

Visa (V): Dominant Payments Leader with Strong Growth Catalysts Ahead

I've always been impressed by how Visa (V) commands the global payments landscape. As an open-loop network, it connects issuers, acquirers, merchants, and consumers without issuing cards or extending credit itself. The VisaNet platform processes over 65,000 transactions per second across more than 200 countries, supporting a ~52% share of the global credit card market and ~60% of debit. This scale generates powerful network effects, where greater adoption benefits everyone involved and creates formidable barriers to entry.
V#SavingsBanks
Arthur Evans, expert
Apr 02, 2026

Johnson & Johnson (JNJ): Targeting $100 Billion in Sales by 2026 Amid Pipeline Strength and MedTech Growth

Following the Kenvue consumer health spin-off, Johnson & Johnson has transformed into a focused healthcare leader, emphasizing Innovative Medicine (pharmaceuticals) and MedTech (devices). In my view, this repositioning sharpens the company's edge in high-margin areas such as oncology, immunology, neuroscience, cardiovascular, surgery, and vision, where its diversified portfolio and R&D efficiency provide clear competitive advantages.
JNJ#PharmaceuticalsMajor
Arthur Evans, expert
Apr 02, 2026